Working… Menu

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty (DECAPUB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00564850
Recruitment Status : Completed
First Posted : November 28, 2007
Results First Posted : December 1, 2011
Last Update Posted : November 22, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to assess the efficacy of triptorelin 11.25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection with triptorelin 11.25 mg.

Condition or disease Intervention/treatment Phase
Precocious Puberty Drug: Triptorelin pamoate 11.25mg (Decapeptyl® SR) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III, Multicentre, Non-comparative, Open and Single Stage Study to Assess the Efficacy and Safety of Pamoate of Triptorelin 11.25 MG in Children With Precocious Puberty
Study Start Date : October 2007
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Arm Intervention/treatment
Experimental: Triptorelin pamoate 11.25mg (Decapeptyl® SR) Drug: Triptorelin pamoate 11.25mg (Decapeptyl® SR)
One intra muscular injection at day 1 and month 3.

Primary Outcome Measures :
  1. Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L [ Time Frame: 3 months after the first injection of triptorelin pamoate 11.25 mg ]

Secondary Outcome Measures :
  1. Number of Participants Whose Intravenous (i.v.) GnRH-stimulated LH Response Was ≤3 IU/L [ Time Frame: Month 6 ]
  2. Follicle Stimulating Hormone (FSH) Level Following GnRH Test [ Time Frame: Screening, month 3 and 6 ]
  3. Basal FSH Level [ Time Frame: Month 0, 1, 2, 3, 4, 5, and 6 ]
  4. Basal LH Level [ Time Frame: Month 0, 1, 2, 3, 4, 5 and 6 ]
  5. Number of Girls With Oestradiol Levels ≤ 20 pg/ml [ Time Frame: Month 0, 1, 2, 3, 4, 5 and 6 ]
  6. Testosterone Level [ Time Frame: Month 0, 3 and 6 ]
  7. Number of Girls With Inhibin B Levels < 6 pg/ml [ Time Frame: Month 0, 3 and 6 ]
  8. Change From Screening in Pubertal Stage (Tanner Method) at Month 6 [ Time Frame: Between screening and month 6 ]
    Pubertal stage (graded from 1 to 5 for penis and breast development, graded from 1 to 6 for pubic hair development) according to the Tanner method was collected. A low stage (i.e. 1) corresponds to a pre-pubertal stage and a high stage (i.e. 5 or 6) to an adult stage. Any increase of grade was defined as 'increased' and no change in grade or a reduced grade was defined as 'stabilised or reduced'.

  9. Height Standard Deviation Score (SDS) [ Time Frame: Month 0, 3 and 6 ]
    Standard deviation (SD) is a standard term used in growth studies and represents Standard Deviations calculated as the patient value minus the mean divided by the standard deviation. Standard Deviation Scores vary depending on the age and sex of the child.

  10. Body Mass Index (BMI) SDS [ Time Frame: Month 0, 3 and 6 ]
  11. Change From Baseline in Growth Velocity (GV) SDS at Month 6 [ Time Frame: Baseline and month 6 ]

    Change from baseline of GV was calculated as: GV at month 6 - GV at baseline. GV SDS was calculated using SAS algorithm.

    Growth velocity during the study was calculated using the two height measures as: GV = (Height at baseline - Height at screening)*365/delay between two height measures.

  12. Difference Between Bone Age and Chronological Age [ Time Frame: Month 0 and 6 ]
    Bone age was defined according to Greulich and Pyle method. Chronological age was calculated using the date of birth.

  13. Uterine Length [ Time Frame: Month 0, 3 and 6 ]
  14. Triptorelin Plasma Levels [ Time Frame: Month 1, 2, 3, 4, 5 and 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria in the screening phase:

  • Onset of sex characteristics (Tanner method) breast development in girls or testicular enlargement in boys before the age of 8 years in girls and 9 years in boys.
  • Weight ≥ 20 kg.

Inclusion Criteria in the treatment phase:

  • Proven central precocious puberty defined as onset of sex characteristics development (according to Tanner method) diagnosed before the age of 8 years in girls and 9 years in boys.
  • Age at evaluation less than 9 years for girls and 10 years for boys.
  • A pubertal response of LH to GnRH test in both sexes (stimulated LH ≥ 5 IU/l).
  • Difference Bone age (BA) (according to Greulich et Pyle method) - Chronological age (CA) > 1 year.
  • Testosterone level ≥ 0.5 ng/ml in boys.

Exclusion Criteria:

  • Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion.
  • Patient with a cerebral tumour requiring a neurosurgery or cerebral irradiation.
  • Patient with a Body Weight ≥ 125% of the ideal weight for the height and age (growth curves).
  • The patient has received a previous treatment with a GnRH analogue, or medroxyprogesterone or cyproterone acetate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00564850

Layout table for location information
Hôpital Hotel-Dieu (CHU)
Angers, France, 49033
Hôpital Saint-Jacques
Besancon, France, 25030
Medical Centre
Bordeaux, France, 33000
Hôpital du Bocage
Dijon, France, 21034
Hôpital Flaubert
Le Havre, France, 76083
Hôpital Jeanne de Flandre
Lille, France, 59037
Hôpital Debrousse
Lyon, France, 69322
Hôpital de la Timone Enfants
Marseille, France, 13385
Hôpital Archet 2
Nice, France, 06202
Hôpital Trousseau
Paris, France, 75012
Hôpital St-Vincent de Paul
Paris, France, 75014
Hôpital Necker - Enfants Malades
Paris, France, 75015
Hôpital Robert Debré
Paris, France, 75019
American Memorial Hospital
Reims, France, 51092
Hôpital Charles Nicolle
Rouen, France, 76031
Hôpital Hautepierre
Strasbourg, France, 67100
Hôpital de la Gespe
Tarbes, France, 65013
Hôpital des Enfants
Toulouse, France, 31026
Sponsors and Collaborators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen

Layout table for additonal information
Responsible Party: Ipsen Identifier: NCT00564850     History of Changes
Other Study ID Numbers: 2-54-52014-143
2005-005644-11 ( EudraCT Number )
First Posted: November 28, 2007    Key Record Dates
Results First Posted: December 1, 2011
Last Update Posted: November 22, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Puberty, Precocious
Gonadal Disorders
Endocrine System Diseases
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents